Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News
On March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the initial dosing, marking the commencement of the Phase IV clinical stage.
Efung Capital first invested in Oryzogen in 2016 and has continued to increase its commitment, participating in two consecutive financing rounds. Over more than a decade, Efung Capital has adhered to the philosophy of "deep empowerment and patient capital," providing not only financial support but also ongoing value-added assistance in areas such as industry resource connections. This partnership has helped Oryzogen tackle the world-class challenge of industrializing recombinant human albumin production.
Looking ahead, Efung Capital will continue to stand alongside Oryzogen, jointly advancing sustained breakthroughs and value growth in the field of innovative biologics in China, bringing "Created in China" benefits to more patients.